Indian CROs and CDMOs are attracting a lot of attention as companies, such as Syngene, Suven, and Divis, create long-term relationships with top pharma organisations. According to Cyndrella Carvalho of JM Financial, India still has a vital untapped CRO market, and with its large and diverse population, it offers enormous potential for growth in medical research. The market is so tight that even larger unlisted businesses, such as India's Aragen, are making a name for themselves.
